JP2005538104A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005538104A5 JP2005538104A5 JP2004524692A JP2004524692A JP2005538104A5 JP 2005538104 A5 JP2005538104 A5 JP 2005538104A5 JP 2004524692 A JP2004524692 A JP 2004524692A JP 2004524692 A JP2004524692 A JP 2004524692A JP 2005538104 A5 JP2005538104 A5 JP 2005538104A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- weight
- simvastatin
- bha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 27
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 14
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 11
- 235000010388 propyl gallate Nutrition 0.000 claims 11
- 239000000473 propyl gallate Substances 0.000 claims 11
- 229940075579 propyl gallate Drugs 0.000 claims 11
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 11
- 229960002855 simvastatin Drugs 0.000 claims 11
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 10
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 9
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical group COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 9
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 9
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 8
- 229960000815 ezetimibe Drugs 0.000 claims 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 7
- 229960001681 croscarmellose sodium Drugs 0.000 claims 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 7
- 235000019359 magnesium stearate Nutrition 0.000 claims 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 5
- 239000008101 lactose Substances 0.000 claims 5
- 239000003381 stabilizer Substances 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- NTOZOESJXIBDLD-UHFFFAOYSA-L [Ca+2].[O-]S(=O)S([O-])(=O)=O Chemical compound [Ca+2].[O-]S(=O)S([O-])(=O)=O NTOZOESJXIBDLD-UHFFFAOYSA-L 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39869102P | 2002-07-26 | 2002-07-26 | |
| PCT/US2003/022889 WO2004010993A1 (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008150227A Division JP2008291034A (ja) | 2002-07-26 | 2008-06-09 | コレステロール吸収阻害剤、ＨＭＧ−ＣｏＡレダクターゼ阻害剤および安定化剤を含有する組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005538104A JP2005538104A (ja) | 2005-12-15 |
| JP2005538104A5 true JP2005538104A5 (cg-RX-API-DMAC7.html) | 2008-07-17 |
Family
ID=31188454
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004524692A Pending JP2005538104A (ja) | 2002-07-26 | 2003-07-22 | コレステロール吸収阻害剤、ＨＭＧ−ＣｏＡレダクターゼ阻害剤および安定化剤を含有する組成物 |
| JP2008150227A Withdrawn JP2008291034A (ja) | 2002-07-26 | 2008-06-09 | コレステロール吸収阻害剤、ＨＭＧ−ＣｏＡレダクターゼ阻害剤および安定化剤を含有する組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008150227A Withdrawn JP2008291034A (ja) | 2002-07-26 | 2008-06-09 | コレステロール吸収阻害剤、ＨＭＧ−ＣｏＡレダクターゼ阻害剤および安定化剤を含有する組成物 |
Country Status (38)
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| DE602004008100T2 (de) * | 2003-11-10 | 2008-04-30 | Microbia Inc., Cambridge | 4-biarylyl-1-phenylazetidin-2-one |
| US7871998B2 (en) | 2003-12-23 | 2011-01-18 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
| KR100598326B1 (ko) * | 2004-04-10 | 2006-07-10 | 한미약품 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법 |
| US20060046996A1 (en) * | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| EP1741427A1 (en) | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
| EP1905424A3 (en) * | 2006-02-02 | 2008-04-30 | Ranbaxy Laboratories Limited | Process for the preparation of a pharmaceutical composition comprising stabilized statin particles |
| US20070275075A1 (en) * | 2006-03-06 | 2007-11-29 | Ilan Zalit | Ezetimibe compositions |
| AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
| DK2526932T3 (en) | 2006-06-19 | 2017-07-17 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| CN1994296B (zh) * | 2006-08-02 | 2010-06-16 | 浙江京新药业股份有限公司 | 一种含有辛伐他汀的药物制剂 |
| GB0713707D0 (en) | 2007-07-13 | 2007-08-22 | Generics Uk Ltd | Stable compositions |
| JP2010534644A (ja) * | 2007-07-27 | 2010-11-11 | シプラ・リミテッド | 医薬組成物およびその製造方法 |
| WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
| EP2231118B2 (en) * | 2007-12-17 | 2017-05-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Suspension comprising non-micronized ezetimibe micro-particles |
| US20090233898A1 (en) * | 2008-03-11 | 2009-09-17 | Glenmark Generics Ltd | Pharmaceutical Compositions Comprising Simvastatin and Ezetimibe |
| TR200806302A2 (tr) * | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Çözünürlük ve stabilite artırıcı farmasötik formülasyon. |
| EP2168573A1 (en) * | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations comprising ezetimibe |
| MX344885B (es) * | 2008-11-10 | 2017-01-10 | Psicofarma S A De C V | Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido. |
| EP2204170A1 (en) * | 2008-12-01 | 2010-07-07 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising ezetimibe and simvastatin |
| WO2010066687A2 (en) * | 2008-12-11 | 2010-06-17 | Dsm Ip Assets B.V. | Stabalized statin-comprising compositions |
| EP2216016A1 (en) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| WO2011002422A2 (en) * | 2009-07-02 | 2011-01-06 | Bilgic Mahmut | Solubility enhancing pharmaceutical formulation |
| WO2011019326A2 (en) * | 2009-07-02 | 2011-02-17 | Mahmut Bilgic | Solubility and stability enchancing pharmaceutical formulation |
| WO2011002424A2 (en) * | 2009-07-02 | 2011-01-06 | Bilgic Mahmut | Solubility and stability enchancing pharmaceutical formulation |
| EP2368543A1 (en) | 2010-03-25 | 2011-09-28 | KRKA, tovarna zdravil, d.d., Novo mesto | Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe |
| KR101302243B1 (ko) * | 2010-07-28 | 2013-09-02 | 씨제이제일제당 (주) | 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물 |
| CN101978953A (zh) * | 2010-10-11 | 2011-02-23 | 上海交通大学 | 基于易吸湿性辅料的固体制剂 |
| EP2468258A1 (en) | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
| US20140141090A1 (en) | 2011-02-02 | 2014-05-22 | Edward S. Wilson | Pharmaceutical Composition Comprising Opioid Agonist And Sequestered Antagonist |
| CN102266323B (zh) * | 2011-08-04 | 2013-03-27 | 海南锦瑞制药股份有限公司 | 依折麦布和辛伐他汀组合物及其制备方法 |
| US9592296B2 (en) | 2011-09-08 | 2017-03-14 | Hexal Ag | Pharmaceutical composition for oral administration with a statin |
| WO2013166114A1 (en) * | 2012-05-01 | 2013-11-07 | Althera Life Sciences, Llc | Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe |
| SI2844233T1 (sl) * | 2012-05-01 | 2020-08-31 | Althera Life Sciences, Llc | Peroralna tableta, sestavljena iz fiksne kombinacije rosuvastatina in ezetimiba za zdravljenje hiperlipidemije in bolezni srca in ožilja |
| RU2547574C2 (ru) * | 2013-07-09 | 2015-04-10 | Общество с ограниченной ответственностью "Трейдсервис" | Лекарственная форма гиполипидемического действия и способ ее изготовления |
| CN103585146B (zh) * | 2013-11-09 | 2015-04-01 | 北京中申专利科技有限公司 | 辛伐他汀的药物组合物 |
| TWI586380B (zh) * | 2013-12-18 | 2017-06-11 | 夢製藥公司 | 包含ＨＭＧ－ＣｏＡ還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑 |
| CN104306348B (zh) * | 2014-09-30 | 2017-05-31 | 地奥集团成都药业股份有限公司 | 一种辛伐他汀片及其制备方法 |
| CA3000016A1 (en) * | 2015-11-06 | 2017-05-11 | Gemphire Therapeutics Inc. | Gemcabene combinations for the treatment of cardiovascular disease |
| CN106937952A (zh) * | 2016-01-04 | 2017-07-11 | 重庆华邦制药有限公司 | 依折麦布和辛伐他汀的制剂 |
| EP3281649A1 (en) * | 2016-08-09 | 2018-02-14 | Teleflex Lifesciences | Wetting agent formulation |
| JP6937195B2 (ja) * | 2017-09-01 | 2021-09-22 | 興和株式会社 | 医薬組成物 |
| US11622939B2 (en) * | 2017-11-23 | 2023-04-11 | Zhejiang Hisun Pharmaceutical Co., Ltd. | HS-25 tablet and preparation method therefor |
| US11833133B2 (en) * | 2020-08-13 | 2023-12-05 | Orient Pharma Co., Ltd. | Solid oral pharmaceutical composition |
| TWI760067B (zh) * | 2020-08-13 | 2022-04-01 | 友霖生技醫藥股份有限公司 | 固態口服醫藥組成物 |
| CN112168801A (zh) * | 2020-10-22 | 2021-01-05 | 哈药集团技术中心 | 一种辛伐他汀片的制备方法 |
| CN115227659B (zh) * | 2022-08-19 | 2023-05-02 | 北京百奥药业有限责任公司 | 一种依折麦布辛伐他汀组合物及其制备方法 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
| AU1422388A (en) | 1987-01-27 | 1988-08-10 | Warner-Lambert Company | Lipid regulating compositions |
| US4820850A (en) | 1987-07-10 | 1989-04-11 | Merck & Co., Inc. | Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof |
| US4916239A (en) | 1988-07-19 | 1990-04-10 | Merck & Co., Inc. | Process for the lactonization of mevinic acids and analogs thereof |
| US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| CA2040865C (en) | 1990-05-15 | 2002-07-23 | James L. Bergey | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
| US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
| IL100091A (en) * | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5688787A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
| US5688785A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| TW223059B (cg-RX-API-DMAC7.html) | 1991-07-23 | 1994-05-01 | Schering Corp | |
| US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| CA2085871C (en) * | 1991-12-27 | 2002-05-07 | Gerald S. Rork | A controlled release drug dispersion delivery device |
| LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| LT3595B (en) * | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| JPH06247854A (ja) * | 1993-02-24 | 1994-09-06 | Ss Pharmaceut Co Ltd | アスコルビン酸含有組成物 |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5976570A (en) * | 1993-12-21 | 1999-11-02 | Applied Analytical Industries, Inc. | Method for preparing low dose pharmaceutical products |
| US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
| US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| WO1995035277A1 (en) * | 1994-06-20 | 1995-12-28 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US6268392B1 (en) * | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| EP0782451A1 (en) * | 1994-09-20 | 1997-07-09 | Pfizer Inc. | Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor |
| US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5624920A (en) | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| SK283552B6 (sk) * | 1995-10-31 | 2003-09-11 | Schering Corporation | 2-Azetidinóny substituované cukrovými zvyškami, farmaceutický prípravok, kombinovaný farmaceutický prípravok a ich použitie |
| US6673831B1 (en) | 1996-04-17 | 2004-01-06 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
| EP0904082A4 (en) * | 1996-04-17 | 2001-09-26 | Merck & Co Inc | COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES |
| WO1998001119A2 (en) | 1996-07-09 | 1998-01-15 | Merck & Co., Inc. | Pharmaceutical compositions comprising simvastatin |
| FR2751540B1 (fr) * | 1996-07-26 | 1998-10-16 | Sanofi Sa | Composition pharmaceutique antithrombotique |
| US5952003A (en) * | 1996-08-01 | 1999-09-14 | Novartis Corporation | Terazosin capsules |
| US6251852B1 (en) * | 1996-09-18 | 2001-06-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
| US6235706B1 (en) * | 1996-09-18 | 2001-05-22 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
| US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| US6245797B1 (en) * | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| WO1999066930A1 (en) | 1998-06-24 | 1999-12-29 | Merck & Co., Inc. | Compositions and methods for treating elevated blood cholesterol |
| JP2002518448A (ja) | 1998-06-24 | 2002-06-25 | メルク エンド カムパニー インコーポレーテッド | 高血中コレステロールを治療する組成物および方法 |
| US6099865A (en) * | 1998-07-08 | 2000-08-08 | Fmc Corporation | Croscarmellose taste masking |
| US6268352B1 (en) * | 1998-09-02 | 2001-07-31 | The Regents Of The University Of California | Promoters of neural regeneration |
| JP2000109882A (ja) * | 1998-10-01 | 2000-04-18 | Nof Corp | 油性粉末、製造方法および用途 |
| SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
| EP1163203A1 (en) | 1999-03-08 | 2001-12-19 | Merck & Co., Inc. | Crystalline hydrated dihydroxy open-acid simvastatin calcium salt |
| EP1161236A1 (en) | 1999-03-08 | 2001-12-12 | Merck & Co., Inc. | Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors |
| US6569461B1 (en) * | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
| ATE306263T1 (de) | 1999-03-10 | 2005-10-15 | Searle Llc | Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere |
| JP2000302672A (ja) * | 1999-04-16 | 2000-10-31 | Taisho Pharmaceut Co Ltd | 咀嚼可能な被覆錠剤 |
| JP3732039B2 (ja) * | 1999-05-21 | 2006-01-05 | 三菱化学フーズ株式会社 | 錠剤用組成物 |
| MXPA02001196A (es) | 1999-08-03 | 2003-02-12 | Lilly Icos Llc | Composiciones farmaceuticas de °-carbolina. |
| US6328995B1 (en) * | 1999-09-24 | 2001-12-11 | Basf Aktiengesellschaft | Stable vitamin and/or carotenoid products in powder form and process for their production |
| ES2240209T3 (es) * | 1999-12-08 | 2005-10-16 | Pharmacia Corporation | Composiciones de eplerenona nanoparticulada. |
| AU2276801A (en) | 1999-12-20 | 2001-07-03 | Schering Corporation | Extended release oral dosage composition |
| US6248359B1 (en) | 2000-01-05 | 2001-06-19 | Laboratorios Phoenix U.S.A., Inc. | Multi-tablet oxybutynin system for treating incontinence |
| EE05442B1 (et) | 2000-02-29 | 2011-08-15 | Bristol-Myers Squibb Company | Vikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks |
| CA2421018A1 (en) * | 2000-09-06 | 2002-03-14 | Merck & Co., Inc. | Dihydroxy open-acid salt of simvastatin |
| JP4351842B2 (ja) * | 2000-12-20 | 2009-10-28 | シェーリング コーポレイション | 低コレステロール血症剤として有用な糖置換２−アゼチジノン |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| DK1354888T3 (da) * | 2000-12-28 | 2009-09-21 | Kissei Pharmaceutical | Glukopyranosyloxypyrazolderivater og anvendelse deraf i medikamenter |
| PT1355644E (pt) | 2001-01-26 | 2006-11-30 | Schering Corp | Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia |
| NZ545332A (en) | 2001-01-26 | 2007-09-28 | Schering Corp | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| WO2002058733A2 (en) | 2001-01-26 | 2002-08-01 | Schering Corporation | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| MEP27808A (en) | 2001-01-26 | 2010-10-10 | Schering Corp | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| NZ542090A (en) | 2001-01-26 | 2006-09-29 | Schering Corp | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
| AU2002258605B2 (en) | 2001-03-28 | 2006-01-12 | Merck Sharp & Dohme Corp. | Enantioselective synthesis of azetidinone intermediate compounds |
| AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
-
2003
- 2003-07-16 AR AR20030102560A patent/AR040588A1/es unknown
- 2003-07-17 MY MYPI20032695A patent/MY148689A/en unknown
- 2003-07-21 PE PE2003000726A patent/PE20050128A1/es not_active Application Discontinuation
- 2003-07-22 RS RSP-2008/0072A patent/RS20080072A/sr unknown
- 2003-07-22 EA EA200500279A patent/EA008888B1/ru not_active IP Right Cessation
- 2003-07-22 AT AT03771709T patent/ATE393628T1/de not_active IP Right Cessation
- 2003-07-22 NZ NZ537611A patent/NZ537611A/en not_active IP Right Cessation
- 2003-07-22 PL PL03375065A patent/PL375065A1/xx not_active Application Discontinuation
- 2003-07-22 HR HR20050081A patent/HRP20050081A2/xx not_active Application Discontinuation
- 2003-07-22 JP JP2004524692A patent/JP2005538104A/ja active Pending
- 2003-07-22 KR KR1020087017824A patent/KR20080070089A/ko not_active Ceased
- 2003-07-22 EP EP03771709A patent/EP1531805B1/en not_active Revoked
- 2003-07-22 GT GT200300149AK patent/GT200300149AA/es unknown
- 2003-07-22 CA CA002493076A patent/CA2493076A1/en not_active Abandoned
- 2003-07-22 KR KR1020057001458A patent/KR20050045993A/ko not_active Ceased
- 2003-07-22 CN CNB038178443A patent/CN1310643C/zh not_active Expired - Fee Related
- 2003-07-22 RS YUP-2005/0061A patent/RS50419B/sr unknown
- 2003-07-22 ME MEP-2008-47A patent/ME00008B/me unknown
- 2003-07-22 UA UAA200501756A patent/UA82489C2/uk unknown
- 2003-07-22 DK DK03771709T patent/DK1531805T3/da active
- 2003-07-22 ME MEP-308/08A patent/MEP30808A/xx unknown
- 2003-07-22 BR BR0312933-0A patent/BR0312933A/pt not_active IP Right Cessation
- 2003-07-22 AU AU2003261217A patent/AU2003261217B2/en not_active Ceased
- 2003-07-22 SI SI200331222T patent/SI1531805T1/sl unknown
- 2003-07-22 CN CNA2007100850256A patent/CN101069684A/zh active Pending
- 2003-07-22 MX MXPA05001004A patent/MXPA05001004A/es active IP Right Grant
- 2003-07-22 IL IL16627903A patent/IL166279A0/xx unknown
- 2003-07-22 DE DE60320652T patent/DE60320652T2/de not_active Revoked
- 2003-07-22 EP EP08103776A patent/EP1992343A1/en not_active Withdrawn
- 2003-07-22 PA PA20038577901A patent/PA8577901A1/es unknown
- 2003-07-22 US US10/625,004 patent/US7229982B2/en not_active Expired - Fee Related
- 2003-07-22 WO PCT/US2003/022889 patent/WO2004010993A1/en not_active Ceased
- 2003-07-22 ME MEP-2008-308A patent/ME00207B/me unknown
- 2003-07-22 GE GEAP8662A patent/GEP20084443B/en unknown
- 2003-07-22 GT GT200300149A patent/GT200300149A/es unknown
- 2003-07-22 HR HR20080518A patent/HRP20080518A2/xx not_active Application Discontinuation
- 2003-07-22 PT PT03771709T patent/PT1531805E/pt unknown
- 2003-07-22 ES ES03771709T patent/ES2303603T3/es not_active Expired - Lifetime
- 2003-07-25 TW TW092120442A patent/TW200412944A/zh unknown
- 2003-07-25 TW TW097131985A patent/TW200906388A/zh unknown
-
2005
- 2005-01-10 ZA ZA200500196A patent/ZA200500196B/en unknown
- 2005-01-10 IS IS7637A patent/IS7637A/is unknown
- 2005-01-25 EC EC2005005573A patent/ECSP055573A/es unknown
- 2005-01-26 TN TNP2005000022A patent/TNSN05022A1/en unknown
- 2005-02-11 MA MA28095A patent/MA27289A1/fr unknown
- 2005-02-25 NO NO20051033A patent/NO20051033L/no unknown
-
2007
- 2007-03-12 US US11/716,595 patent/US20070160666A1/en not_active Abandoned
-
2008
- 2008-02-26 CR CR9767A patent/CR9767A/es unknown
- 2008-02-28 EC EC20080055732008005573A patent/ECSP085573A/es unknown
- 2008-03-12 US US12/047,223 patent/US20080275020A1/en not_active Abandoned
- 2008-05-08 NO NO20082156A patent/NO20082156L/no not_active Application Discontinuation
- 2008-05-11 IL IL191348A patent/IL191348A0/en unknown
- 2008-06-09 JP JP2008150227A patent/JP2008291034A/ja not_active Withdrawn
- 2008-06-17 AR ARP080102576A patent/AR067030A2/es not_active Application Discontinuation
-
2009
- 2009-02-26 AU AU2009200768A patent/AU2009200768A1/en not_active Abandoned
- 2009-05-26 US US12/472,021 patent/US7718643B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005538104A5 (cg-RX-API-DMAC7.html) | ||
| AU2003261217B2 (en) | Composition comprising a cholesterol absorption inhibitor, an HMG-CoA reductase inhibitor and a stabilizing agent | |
| MX2010010479A (es) | Capsula para la prevencion de enfermedades cardiovasculares. | |
| JP2013526516A (ja) | ＨＭＧ−ＣｏＡ還元酵素阻害剤及びイルベサルタンを含む二層錠の薬学的剤型 | |
| JP2004532828A5 (cg-RX-API-DMAC7.html) | ||
| CN115025060A (zh) | 含ω-3脂肪酸酯和他汀类的口服给药复合制剂 | |
| JP2009527577A (ja) | フルバスタチンナトリウム医薬組成物 | |
| JP2008534592A5 (cg-RX-API-DMAC7.html) | ||
| EP2328563A1 (en) | Solubility enhancing pharmaceutical formulation | |
| WO2023281089A3 (en) | Pharmaceutical composition comprising naproxen and paracetamol | |
| JP2007512287A5 (cg-RX-API-DMAC7.html) | ||
| AU2004292768A1 (en) | Compositions comprising organic compounds | |
| JPWO2020047311A5 (cg-RX-API-DMAC7.html) | ||
| CN101094667A (zh) | 包含他汀类药物和抗气胀剂的降胆固醇组合物 | |
| JP2018507176A (ja) | Ａｕｃによるオルメサルタン投与のための方法 | |
| RU2024101683A (ru) | Фармацевтическая композиция, содержащая напроксен и парацетамол | |
| JP2007532624A5 (cg-RX-API-DMAC7.html) | ||
| JP2013035770A (ja) | 安定化された医薬組成物 | |
| JP2007290975A (ja) | プランルカスト錠剤 | |
| WO2010021609A1 (en) | Solubility and stability enhancing pharmaceutical formulation | |
| JP2008133231A (ja) | 光安定性が改善された医薬組成物 | |
| HK1125578A (en) | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent | |
| HK1080384B (en) | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent | |
| KR20100112292A (ko) | 플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법 |